Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA3 | P07451 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422912 | 0.97 | LMNA (0.50) | LMNAGSRNFKB1RNPEPALDH1A1 | |
| SCHEMBL15861710 | 0.97 | LMNA (0.50) | LMNAGSRNFKB1RNPEPALDH1A1 | |
| SCHEMBL5015299 | 0.97 | LMNA (0.50) | LMNAGSRNFKB1RNPEPALDH1A1 | |
| SCHEMBL1050623 | 0.91 | — | — | |
| SCHEMBL20639323 | 0.89 | LMNA (0.48) | LMNAGSRNFKB1RNPEPALDH1A1 | |
| SCHEMBL31526867 | 0.85 | LMNA (0.48) | LMNAGSRNFKB1RNPEPALDH1A1 | |
| SCHEMBL8061903 | 0.85 | ALDH1A1 (0.62) | LMNAGSRRNPEPALDH1A1TSHR | |
| SCHEMBL23048319 | 0.83 | LMNA (0.67) | LMNAALDH1A1TSHRDNM1BLM | |
| SCHEMBL17062955 | 0.83 | ALDH1A1 (0.60) | LMNAALDH1A1TSHRDNM1BLM | |
| SCHEMBL14136512 | 0.83 | LMNA (0.60) | LMNAALDH1A1TSHRDNM1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121363052-B | Ageing-resistant polyethylene-based dyed fiber and preparation method thereof | GUANGDONG BIEM.L.FDLKK GOLF GARMENT Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-119236980-A | VPO catalyst and application thereof in maleic anhydride preparation by n-butane oxidation | 万华化学集团股份有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118127663-A | Method for preparing flame-retardant DTY polyester yarns by regenerating polyester fibers | 安徽保尔盈新材料科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-117534765-A | CD 28-targeting trispecific antibody construction method | 北京大学深圳研究生院 | 2024-02-09 | — | — | CN | claimed |
| CN-113861403-A | Nano material and preparation method and application thereof | 北京化工大学 | 2021-12-31 | — | — | CN | claimed |
| US-20200016264-A1 | NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | CUREVAC AG (DE) | 2020-01-16 | — | — | US | claimed |
| US-10441653-B2 | Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant | CUREVAC AG (DE) | 2019-10-15 | — | — | US | claimed |
| EP-3270949-A2 | INSULIN ANALOGUES CONTAINING A GLUCOSE-REGULATED CONFORMATIONAL SWITCH | Case Western Reserve University (US) | 2018-01-24 | — | — | EP | claimed |
| WO-2016149222-A2 | INSULIN ANALOGUES CONTAINING A GLUCOSE-REGULATED CONFORMATIONAL SWITCH | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-22 | — | — | WO | claimed |
| CN-101874112-B | Formula (I) especially as immunostimulant/adjuvant: GlXmGn or formula (II): the nucleic acid of ClXmCn | 库瑞瓦格股份公司 | 2016-08-24 | — | — | CN | claimed |
| EP-1628531-A2 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS | HYBRIDON, INC. (US) | 2006-03-01 | — | — | EP | claimed |
| US-20050026858-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2005-02-03 | — | — | US | claimed |
| US-20050009773-A1 | Using oligonucleotide immunostimulant mixture with drug | HYBRIDON, INC. | 2005-01-13 | — | — | US | claimed |
| US-20040266710-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2004-12-30 | — | — | US | claimed |
| WO-2004103301-A2 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS | HYBRIDON, INC. (US) | 2004-12-02 | — | — | WO | claimed |
| US-20040198685-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | HYBRIDON, INC. | 2004-10-07 | — | — | US | claimed |
| US-20040136948-A1 | Branched immunomodulatory compounds and methods of using the same | DYNAVAX TECHNOLOGIES CORPORATION | 2004-07-15 | — | — | US | claimed |
| US-20040097719-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | HYBRIDON, INC. | 2004-05-20 | — | — | US | claimed |
| EP-1393745-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends | HYBRIDON, INC. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20020137714-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2002-09-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009773-A1 | Using oligonucleotide immunostimulant mixture with drug | TLR3, TLR9, CD47 | LMNA 4781/4885GSR 1444/4885NFKB1 256/4885 |
| US-20040136948-A1 | Branched immunomodulatory compounds and methods of using the same | IFNG, ICOS, IL2 | LMNA 4303/4885GSR 1674/4885NFKB1 378/4885 |
| US-20020137714-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | LMNA 4812/4885GSR 1754/4885NFKB1 336/4885 |
| US-20040198685-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | NT5C2, ENTPD5, TLR5 | LMNA 4834/4885GSR 1664/4885NFKB1 538/4885 |
| US-20040266710-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | LMNA 4812/4885GSR 1754/4885NFKB1 336/4885 |
| US-20040097719-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | TLR5, TLR3, ENTPD5 | LMNA 4649/4885GSR 3334/4885NFKB1 369/4885 |
| US-20200016264-A1 | NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | TLR9, TLR3, TLR5 | LMNA 479/4885GSR 529/4885NFKB1 498/4885 |
| US-20050026858-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | LMNA 4812/4885GSR 1754/4885NFKB1 336/4885 |
| US-10441653-B2 | Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant | TLR9, TLR7, GMNN | LMNA 1341/4885GSR 299/4885NFKB1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.